Zydus Lifesciences shares in focus after FDA approval for prostate cancer drug

March 19, 2025

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.

More To Explore

Why bank stocks are an oasis for investors in a desert of chaos

Banking and financial services have outperformed in 2025, with Bank Nifty and Nifty Financial Services gaining over 8% and 12%. Strong fundamentals, supportive RBI policy,

April 26, 2025

How a Rs 40,000 monthly SIP is helping one father secure his daughter’s dreams and his retirement

Mumbai’s Harsh Jain showcases how disciplined SIP investing can secure major life goals like education, marriage, and retirement. With a Rs 40,000 monthly SIP and

April 26, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003